New data show Rinvoq bests Dupixent in atopic dermatitis study

US pharma major AbbVie (NYSE: ABBV) on Thursday announced positive top-line results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of Rinvoq (upadacitinib).

The study compared Rinvoq 15mg once daily starting dose and dose-adjusted based on clinical response versus dupilumab per its labeled dose in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable.

Dupilumab is the active ingredient of Regeneron (Nasdaq: REGN) and Sanofi’s (Euronext: SAN) blockbuster drug Dupixent, which notched up sales of 2.84 billion euros ($3 billion)) for the French drug major.